ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics Inc ADMA closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.

  • The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the obligations under the Perceptive Advisors senior secured notes.
  • As previously disclosed, ADMA has engaged Morgan Stanley MS as an advisor to evaluate various strategic and financing alternatives.
  • Earnings: ADMA reported Q4 sales of $26.4 million, +89% Y/Y, beating the consensus of $21.76 million.
  • The growth was favorably impacted by the continued commercial ramp-up of the Intravenous Immunoglobulin product portfolio.
  • The company reported a Q4 EPS loss of $(0.09) versus $(0.20) and is in line with the consensus.
  • Guidance: ADMA anticipates more than $125 million in FY22 revenues, exceeding the consensus of $112.77 million.
  • The FDA has also approved extending the expiration dating from 24 to 36 months for ADMA Biologics' ASCENIV and BIVIGAM immune globulin drug product stored at 2-8°C. 
  • The expiration date extension applies to all existing ASCENIV and BIVIGAM lots in the commercial supply chain and future production.
  • Price Action: ADMA shares are up 2.67% at $1.54 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareFinancingFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!